-+ 0.00%
-+ 0.00%
-+ 0.00%

Sana plans SG293 in vivo CAR-T trial in non-Hodgkin lymphoma later 2026

PUBT·05/12/2026 20:09:33
Listen to the news
Sana plans SG293 in vivo CAR-T trial in non-Hodgkin lymphoma later 2026
  • Sana Biotechnology presented preclinical data at ASGCT 2026 for in vivo CAR T candidate SG293 surrogate, positioning program for a first clinical study in non-Hodgkin lymphoma later in 2026.
  • Non-human primate results showed selective delivery to target immune cells, generation of functional CAR T cells, deep B-cell depletion, without use of lymphodepleting chemotherapy.
  • Tissue analyses indicated no meaningful delivery to key non-target organs, with side effects described as mild to manageable in this model.
  • Company also guided to a clinical start for BCMA-targeted in vivo CAR T candidate SG227 in multiple myeloma as early as mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121605PRIMZONEFULLFEED9718773) on May 12, 2026, and is solely responsible for the information contained therein.